The table below shows CytomX Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$76.20M
$138.10M
$101.21M
$53.16M
$37.31M
$68.43M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$68.73M
$83.38M
$77.68M
$111.65M
$114.19M
$112.94M
SG&A
CTMX annual revenue (10-K history)
CytomX Therapeutics, Inc. reported annual revenue of $76.20M for fiscal year 2025. That is down 44.8% from $138.10M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $15.04M (FY 2016) to $76.20M. Figures come from the company's audited annual reports as filed with the SEC.